Anna B Lebouille-Veldman, Tom W J Huizinga, Rania A Mekary, Carmen L A Vleggeert-Lankamp
{"title":"长期使用糖皮质激素和类风湿关节炎相关的颈椎畸形。","authors":"Anna B Lebouille-Veldman, Tom W J Huizinga, Rania A Mekary, Carmen L A Vleggeert-Lankamp","doi":"10.1007/s10067-025-07408-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>RA patients are often prescribed glucocorticoids, although it is known that their long-term use increases the risk of osteoporosis and fractures. The association between glucocorticoid use and RA-associated cervical spine deformity is yet to be determined.</p><p><strong>Method: </strong>Duration and dose of glucocorticoid use were evaluated in patients with new onset RA (BeSt Trial). Missing values on the exposure were imputed using the last observation carried forward. Lateral X-rays at 5- and 10-year follow-ups were assessed for atlantoaxial subluxation (AAS) and subaxial subluxation (SAS). To estimate the association between glucocorticoids and cervical spine deformity, multiple logistic regression models adjusted for age, gender, baseline Disease Activity Score (DAS), ACPA positivity, and RF positivity were used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Mediation analysis was performed to evaluate whether such potential association was mediated via mean DAS.</p><p><strong>Results: </strong>Cervical deformity (AAS and/or SAS > 2 mm) was observed in 108 (40%) out of 272 patients. For a 1-year increase in total duration of glucocorticoid use, the adjusted OR for RA-associated cervical spine deformity was 1.19 (95% CI, 1.03-1.38; p = 0.02), and for an increase of 1 g of glucocorticoid in total cumulative dose, the OR was 1.06 (95% CI, 1.01-1.12; p = 0.02). Mediation analysis could not reveal an influence of mean DAS on these associations.</p><p><strong>Conclusions: </strong>There was evidence of a direct association between long-term use of glucocorticoids in newly diagnosed RA patients and RA-associated cervical spine deformity after 10 years. Other effective therapies to suppress disease activity may be preferred over glucocorticoids. Key Points • For a 1-year increase in total duration of prednisone use in RA patients, the adjusted OR for RA-associated cervical spine deformity was 1.17 (95% CI, 1.01-1.36; p = 0.04). • For an increase in total cumulative dose of 1 g of prednisone in RA patients, the adjusted OR for RA-associated cervical spine deformity was 1.06 (95% CI, 1.00-1.11; p = 0.04). • The use of glucocorticoids in RA patients was associated with an increased odds of RA-associated cervical spine deformity after 10 years, which may suggest that other effective therapies to suppress disease activity should be preferred over glucocorticoids.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prolonged glucocorticoid use and rheumatoid arthritis-associated cervical spine deformity.\",\"authors\":\"Anna B Lebouille-Veldman, Tom W J Huizinga, Rania A Mekary, Carmen L A Vleggeert-Lankamp\",\"doi\":\"10.1007/s10067-025-07408-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>RA patients are often prescribed glucocorticoids, although it is known that their long-term use increases the risk of osteoporosis and fractures. The association between glucocorticoid use and RA-associated cervical spine deformity is yet to be determined.</p><p><strong>Method: </strong>Duration and dose of glucocorticoid use were evaluated in patients with new onset RA (BeSt Trial). Missing values on the exposure were imputed using the last observation carried forward. Lateral X-rays at 5- and 10-year follow-ups were assessed for atlantoaxial subluxation (AAS) and subaxial subluxation (SAS). To estimate the association between glucocorticoids and cervical spine deformity, multiple logistic regression models adjusted for age, gender, baseline Disease Activity Score (DAS), ACPA positivity, and RF positivity were used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Mediation analysis was performed to evaluate whether such potential association was mediated via mean DAS.</p><p><strong>Results: </strong>Cervical deformity (AAS and/or SAS > 2 mm) was observed in 108 (40%) out of 272 patients. For a 1-year increase in total duration of glucocorticoid use, the adjusted OR for RA-associated cervical spine deformity was 1.19 (95% CI, 1.03-1.38; p = 0.02), and for an increase of 1 g of glucocorticoid in total cumulative dose, the OR was 1.06 (95% CI, 1.01-1.12; p = 0.02). Mediation analysis could not reveal an influence of mean DAS on these associations.</p><p><strong>Conclusions: </strong>There was evidence of a direct association between long-term use of glucocorticoids in newly diagnosed RA patients and RA-associated cervical spine deformity after 10 years. Other effective therapies to suppress disease activity may be preferred over glucocorticoids. Key Points • For a 1-year increase in total duration of prednisone use in RA patients, the adjusted OR for RA-associated cervical spine deformity was 1.17 (95% CI, 1.01-1.36; p = 0.04). • For an increase in total cumulative dose of 1 g of prednisone in RA patients, the adjusted OR for RA-associated cervical spine deformity was 1.06 (95% CI, 1.00-1.11; p = 0.04). • The use of glucocorticoids in RA patients was associated with an increased odds of RA-associated cervical spine deformity after 10 years, which may suggest that other effective therapies to suppress disease activity should be preferred over glucocorticoids.</p>\",\"PeriodicalId\":10482,\"journal\":{\"name\":\"Clinical Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10067-025-07408-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07408-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:尽管已知长期使用糖皮质激素会增加骨质疏松和骨折的风险,但RA患者通常会被处方糖皮质激素。使用糖皮质激素与 RA 引起的颈椎畸形之间的关系尚未确定:方法:对新发 RA 患者使用糖皮质激素的持续时间和剂量进行评估(BeSt 试验)。对暴露的缺失值使用最后一次观察结果进行估算。对随访5年和10年的侧位X线片进行寰枢椎脱位(AAS)和轴下脱位(SAS)评估。为了估算糖皮质激素与颈椎畸形之间的关系,研究人员使用了多元逻辑回归模型,并对年龄、性别、基线疾病活动评分(DAS)、ACPA阳性和RF阳性进行了调整,以估算出几率比(OR)及其95%置信区间(CI)。结果显示,颈椎畸形(ACPA阳性)与RF阳性之间的潜在联系是通过平均DAS进行中介分析的:在 272 例患者中,有 108 例(40%)观察到颈椎畸形(AAS 和/或 SAS > 2 毫米)。糖皮质激素总使用时间每增加1年,RA相关颈椎畸形的调整OR值为1.19(95% CI,1.03-1.38;P = 0.02),糖皮质激素总累积剂量每增加1克,OR值为1.06(95% CI,1.01-1.12;P = 0.02)。中介分析无法显示平均 DAS 对这些关联的影响:有证据表明,新诊断的RA患者长期使用糖皮质激素与10年后RA相关的颈椎畸形有直接关系。与糖皮质激素相比,其他抑制疾病活动的有效疗法可能更受青睐。要点 - RA患者使用泼尼松的总时间每增加1年,RA相关性颈椎畸形的调整OR值为1.17(95% CI,1.01-1.36;P = 0.04)。- 如果 RA 患者的泼尼松累积总剂量增加 1 克,则 RA 相关性颈椎畸形的调整 OR 为 1.06(95% CI,1.00-1.11;p = 0.04)。- RA患者使用糖皮质激素与10年后RA相关性颈椎畸形的几率增加有关,这可能表明,抑制疾病活动的其他有效疗法应优于糖皮质激素。
Prolonged glucocorticoid use and rheumatoid arthritis-associated cervical spine deformity.
Objectives: RA patients are often prescribed glucocorticoids, although it is known that their long-term use increases the risk of osteoporosis and fractures. The association between glucocorticoid use and RA-associated cervical spine deformity is yet to be determined.
Method: Duration and dose of glucocorticoid use were evaluated in patients with new onset RA (BeSt Trial). Missing values on the exposure were imputed using the last observation carried forward. Lateral X-rays at 5- and 10-year follow-ups were assessed for atlantoaxial subluxation (AAS) and subaxial subluxation (SAS). To estimate the association between glucocorticoids and cervical spine deformity, multiple logistic regression models adjusted for age, gender, baseline Disease Activity Score (DAS), ACPA positivity, and RF positivity were used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Mediation analysis was performed to evaluate whether such potential association was mediated via mean DAS.
Results: Cervical deformity (AAS and/or SAS > 2 mm) was observed in 108 (40%) out of 272 patients. For a 1-year increase in total duration of glucocorticoid use, the adjusted OR for RA-associated cervical spine deformity was 1.19 (95% CI, 1.03-1.38; p = 0.02), and for an increase of 1 g of glucocorticoid in total cumulative dose, the OR was 1.06 (95% CI, 1.01-1.12; p = 0.02). Mediation analysis could not reveal an influence of mean DAS on these associations.
Conclusions: There was evidence of a direct association between long-term use of glucocorticoids in newly diagnosed RA patients and RA-associated cervical spine deformity after 10 years. Other effective therapies to suppress disease activity may be preferred over glucocorticoids. Key Points • For a 1-year increase in total duration of prednisone use in RA patients, the adjusted OR for RA-associated cervical spine deformity was 1.17 (95% CI, 1.01-1.36; p = 0.04). • For an increase in total cumulative dose of 1 g of prednisone in RA patients, the adjusted OR for RA-associated cervical spine deformity was 1.06 (95% CI, 1.00-1.11; p = 0.04). • The use of glucocorticoids in RA patients was associated with an increased odds of RA-associated cervical spine deformity after 10 years, which may suggest that other effective therapies to suppress disease activity should be preferred over glucocorticoids.
期刊介绍:
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.